Biotech Sector Faces Challenges as Hillstream Hits New Low Hillstream Biopharma’s stock dropped to $1.36, reflecting a 74.63% decline over the past year. Despite holding more cash than debt, the firm struggles with weak financial health and clinical setbacks. Analysts remain cautiously optimistic, setting a $5 target price, dependent on strategic recovery efforts and broader market conditions.2